Executive Summary

Investment Thesis: Analysts project substantial upside for $TCNNF based on long term market expansion and assumed recovery in profitability. The company currently carries material operating losses but shows solid liquidity metrics and a market cap that reflects both optionality and execution risk. Near term performance will likely hinge on margin recovery, cost control and progress against state level expansions and regulatory developments.

Current Price: $12.25 | Key Metric: EPS (TTM) $-2.46 | Stance: NEUTRAL

Company Overview

Trulieve Cannabis Corp. operates in the legalized cannabis sector, providing a mix of retail, cultivation and manufacturing services for medical and adult use markets. The company is one of the larger vertically integrated operators in the U.S. cannabis industry and generates revenue from product sales across multiple state markets.

Key Products & Competitive Position

Core Business: Vertically integrated cannabis operator, combining cultivation, processing and retail dispensary operations.
Key Products: Flower, extracts, vape cartridges, edibles and branded medical formulations sold through company-owned retail networks and wholesale channels.
Competitive Moat: Scale in retail footprint and integrated supply chain, brand recognition in key states, and experience with state regulatory frameworks.

Recent Developments

Most recently Trulieve reported Q3 2026 results on August 7, 2026, with an EPS of $-2.11 which missed consensus estimates by a wide margin. Analysts continue to maintain a bullish consensus and elevated price targets despite the profit shortfall. Liquidity metrics remain relatively healthy, as reflected in a current ratio near 6, which gives the company flexibility to fund operations while it works to stabilize margins. What will management focus on next, and how quickly can operating performance normalize?

Financial Snapshot

Market Cap$2.36B

P/E Ratio-4.96

52-Week Range$7.92 - $13.28

Dividend Yield0.0%

EPS (TTM)$-2.46

ROE-44.06%

Revenue & Earnings Trends

Revenue growth in the cannabis sector has been uneven as new adult use markets come online and wholesale pricing compresses in mature states. Trulieve has generated top line expansion at times, but earnings remain negative on a trailing twelve month basis, with EPS at $-2.46. The August 7, 2026 quarter produced an EPS of $-2.11 versus an estimate of $0.06, a meaningful miss that highlights either cost or one time items that materially impacted profitability. Analysts will be watching margin trends closely to see whether the company can return to positive earnings or at least narrow the loss profile.

Balance Sheet Highlights

The balance sheet shows a conservative liquidity position. A current ratio of 5.94 suggests short term obligations are well covered by current assets, which can be an important buffer in a cyclical, capital intensive industry. There is, however, elevated leverage implied by negative equity returns and persistent operating losses. Cash runway is a function of operating cash flow performance and access to capital markets, both of which remain sensitive to investor sentiment toward the sector.

Valuation Analysis

Current Valuation Metrics

Forward P/EN/Avs Industry: N/A

PEG RatioN/AGrowth-adjusted

EV/EBITDAN/Avs Historical: N/A

P/S RatioApproximately 2-4xvs Peers: Varied

Historical Comparison

Trulieve's current market price sits near the top of its 52 week range and well above the 52 week low. Historically the stock has traded at a wide range of multiples reflecting shifts between growth optimism and sector risk aversion. Given negative EPS, typical earnings multiples are less informative and analysts rely more on revenue multiples, scenario DCFs and sum of the parts models tied to state level cash flows.

Fair Value Estimate

Analyst mean and median price targets are materially higher than the current price. The mean target of $47.21 implies large upside from $12.25, but that view depends on assumptions about revenue growth, margin recovery and favorable regulatory outcomes. A conservative valuation, holding current margins and cash flows constant, would imply a far lower per share value than consensus targets. A scenario approach is useful, contrasting a recovery case driven by margin improvement against a downside case reflecting prolonged compression and slower market expansion.

Competitive Landscape

Market Position

Market Share: Meaningful retail and wholesale presence in several U.S. states | Ranking: One of the larger U.S. vertically integrated cannabis operators

Key Competitors

$CLOVCanadian and U.S. focused operator with diversified retail presence

Cronos Group (CRON)Large Canadian LP with expanding U.S. partnerships and scale production

$GTIIRegional operator with rapid retail expansion in multiple states

Competitive Advantages

Moat 1: Retail scale, which helps control margin capture at point of sale
Moat 2: Vertical integration limits reliance on external suppliers and can reduce cost per unit
Moat 3: Experience navigating state level regulatory frameworks

Earnings Track Record

Last 4 Quarters: 0 beats / 1 miss, others not shown

Recent Earnings History

Q3 2026$-2.11 vs $0.06 estMISS

Q2 2026N/AN/A

Q1 2026N/AN/A

Q4 2025N/AN/A

Guidance Trend

Management has not provided robust long term GAAP earnings guidance that materially narrows analyst uncertainty. Given the recent large EPS miss, the market will be watching for updated guidance, incremental disclosures on cost saving initiatives and clearer timeline for returning to positive adjusted EBITDA on a sustained basis.

Analyst Sentiment

Consensus Rating: Strong Buy

Strong Buy: 1 Buy: 5 Hold: 0 Sell: 0

Price Targets

Low: $18
Mean: $47.21 (+285.4% upside)
High: $65

Recent Analyst Actions

Despite the Q3 miss, the analyst community has retained an elevated set of targets, reflecting expectations for medium term industry growth and potential operating leverage. Analysts note that upside scenarios rely on margin recovery and steady market expansion across prioritized states.

Technical Outlook

Current Price: $12.25 vs 52-Week High: $13.28 (-7.8% from high)

Trend Analysis

The share price is trading close to its 52 week high, reflecting the divergence between market optimism and corporate profitability. Momentum has been relatively strong compared with the broader cannabis group, but volatility remains elevated as indicated by a beta of 1.68. Traders will likely react quickly to quarterly results or regulatory headlines.

Key Levels

Resistance: $13.28, $15.00
Support: $10.00, $8.00

Bull vs Bear Case

Bull Case

Catalyst 1: Margin recovery through cost cuts and pricing stabilization could restore profitability and lift EPS multiples.
Catalyst 2: Continued state market expansion and retail rollouts can drive durable revenue growth and higher market share.
Catalyst 3: Analysts' optimistic modeling assumes regulatory progress and improved investor appetite for the sector, which supports higher price targets.

Bull Target: $65 (+431% from current)

Bear Case

Risk 1: Persistent operating losses and failure to return to positive adjusted EBITDA could compress valuation and reduce access to capital.
Risk 2: Regulatory setbacks or slower than expected adult use adoption in key states could limit revenue upside.
Risk 3: High volatility and sector sentiment shifts could drive multiple contraction even if revenue stabilizes.

Bear Target: $9 (-26% from current)

Risks to Consider

Valuation Risk: Current analyst targets imply a material re-rating that depends on improving margins and predictable cash flows. If those do not materialize, downside risk is elevated.
Competitive Risk: The market remains crowded with both large multi state operators and regional specialists, putting pressure on pricing and retail traffic.
Macro Risk: Interest rate environment and broader market sentiment toward speculative sectors can rapidly alter access to capital and share valuations.
Execution Risk: Integrating acquisitions, managing inventory turns and controlling SG&A are operational challenges that can affect near term profitability.

Bottom Line

Investment Verdict: NEUTRAL

Data suggests a split picture for $TCNNF. Sell side analysts project steeper upside based on recovery assumptions and expanding markets, yet near term fundamentals remain challenged as evidenced by a notable EPS miss and negative trailing EPS. Liquidity is a relative strength, but execution and regulatory timing remain the key variables that will determine whether consensus targets are achievable.

Action Items for Investors

Long-term investors: Monitor margin recovery, state market performance and any shifts in regulatory posture that could materially change long term cash flow assumptions. Track quarterly adjusted EBITDA and segment level revenue trends.
Short-term traders: Watch volatility around earnings and headlines, and consider the stock's elevated beta when sizing positions. Near term price action will likely respond to confirmation of margin improvement or further guidance changes.
Risk management: Given the discrepancy between analyst targets and current fundamentals, define position sizing and loss tolerance up front and reassess after upcoming quarterly disclosures.

What to Watch This Week

Any analyst notes revising models after the August 7 earnings miss and subsequent commentary.
State level license or retail expansion announcements that could change near term revenue outlook.
Sector wide regulatory developments or macro headlines that shift risk appetite for cannabis equities.

TCNNF: Analysts Bullish, Fundamentals Mixed